Authors


Bertrand Ducrey

Latest:

The Importance of Collaborative Business Models for Drug Development

Insights and examples of how collaborative efforts can lead to the development of innovative therapies that target unmet patient needs.


Gejaa Gobena

Latest:

Dynamic Compliance: The Best Defense for Pharma

A proactive and tailored compliance department—with the nimbleness to adapt strategies on the fly—is a critical shield for life sciences companies during government investigations.


Ferry Tamtoro

Latest:

How Agile Practices Can Enable Faster, Better Digital Health Products

Providing ultimate value to stakeholders remains key in new style of development.


Justin T. Fleischacker

Latest:

As Pharma Continues to Adapt to AI, the POSA Standard will Need to Equally Adapt

U.S. patent law will have to adapt to the use of AI in the life sciences industry.


Stef Schutte, PharmD, MSc

Latest:

How Regulatory Affairs Is Shaping Tomorrow’s Innovation Landscape

As regulatory reform continues to evolve in the US and Europe, the role of regulatory affairs is poised to help shape the more personalized treatment landscape on the horizon.


William Kimmerle

Latest:

Building Pharma and Lab Spaces in New Jersey 2021–Adapting to Changing Needs

NJ can regain leadership in pharma by offering modern lab spaces for biotech and other lab-based growth companies.


Justin VanNest

Latest:

Making the Case for Early-Stage Commercial Analytics

Analytics capabilities are no longer a nice-to-have, but a necessity to build and maintain a successful business and competitive edge.


Meg Rivers

Latest:

Q&A with Amy West, Head of US Digital Health & Innovation Strategy at Novo Nordisk

Amy West, Head of US Digital Health & Innovation Strategy at Novo Nordisk, shares her insights on fostering collaboration, embracing change, and her compelling vision to revolutionize digital transformation and innovation in the field of healthcare.


Jerry V. Gross

Latest:

Health Tech Companies Lead Charge for Greater Access

Stay-at-home orders during the pandemic forced a shift in patient preferences—and the pharma industry has responded.


Jack Mycka

Latest:

Policy Reforms for Orphan Drugs

Outlook for orphan PRMA environment in the US, EU4, and UK.


Dan Donovan

Latest:

HCPs & Virtual Meetings: What We Learned

Addressing the challenges created by virtual meetings with HCPs, what we have learned about virtual meetings so far, and a look into the future.


Kiana Dixson

Latest:

Addressing the Knowledge Gap in Biologics & Biosimilars: Is a Board Certified Biologics and Biosimilars Program the Answer?

Life sciences professionals will need to keep up with market demand for biologics and biosimilars.


Mark Miller

Latest:

Delivering Brand Relevancy through Connected Data and Analytics

How a large, global biopharma company is leveraging a data-linking strategy to power insight-generation tools and techniques—and supporting customers through their journey with dynamic personalization and modular content.


Pharmaceutical Press

Latest:

Are You Up to Date With the Latest FDA Guidance?

Webinar Date/Time: Tue, Nov 19, 2024 11:00 AM EST



Dr. Wendy Kampman

Latest:

Delivering Medical Affairs Value Through Omnichannel Orchestration

Learnings from a roundtable discussion with Medical Affairs leadership from 11 pharma companies


Ganes Kesari

Latest:

Harnessing the Value of AI In Customer Engagement

By using correct data and pertinent ML algorithms, customer engagement leaders can identify deep insights into customer behavior and make the right interventions to transform the customer experience.


Lise Seger

Latest:

Building an Optimal Patient Support Team

How effective training programs enable ‘next-generation’ patient engagement.


Gareth Shaw

Latest:

Using Identity Resolution Technology to Dispense Hyper-Relevant Information to HCPs

Healthcare professionals (HCPs) shouldn’t miss out on critical information while their focus is on their patients, which is why messages on professional platforms are an essential resource to improve a patient’s health results, writes Gareth Shaw.


Ava Bousher

Latest:

Boosting Clinical Trials and Patient Access with Payer Insights

Clinical studies are increasingly designed to satisfy evidentiary needs.


Luke Forsthoefel

Latest:

Delivery and Disruption: Navigating a Changing Care Terrain

The diversification of site-of-care delivery models is accelerating rapidly, creating new go-to-market implications for drug manufacturers—but also new opportunities to drive more fundamental innovation in engagement and access strategies.


Dr. Simone Seiter

Latest:

Strategic Decision-Making in Early-Stage Drug Development and Lifecycle Management to Maximize a Drug’s Lifetime Value

Presenting a structured, decision-making approach for executive management to make sound strategic decisions for drug development and life cycle management.


Lynn Collins, PhD

Latest:

Succession Attack Plan: Get Strategic with Your Critical Roles

Outlining four considerations for biopharma companies in ensuring that their approach to replacing and filling key leadership positions is more truly aligned with future goals in business delivery and risk management.


Lung-I Cheng, PhD

Latest:

From Potential to Value: Carving a Slice of the CGT ‘PIE'

The importance of pre-approval information exchange (PIE) with payers and other strategic considerations to help navigate today’s market access challenges and regulatory requirements in bringing promising cell and gene therapies to the market.


Donielle McCutcheon

Latest:

This is Your Wake-Up Call–Sunshine Act Enforcement is Here

Mitigating potential risk for stakeholders in light of latest Sunshine Act developments.


Clay Romweber, Brand Insights Contributor, EVP, Chief Growth Officer, BioPharm Communications
Clay Romweber, Brand Insights Contributor, EVP, Chief Growth Officer, BioPharm Communications

Latest:

The Importance of Opinion Leader-Content in a Digital Transformation

Marketers are working to reimagine how they leverage key opinion leader (KOL) support during COVID-19.



Amy Brown

Latest:

Identifying Healthcare Trends from Conversation Data

Healthcare customers and patients are facing more avenues to receive misinformation about drugs than ever before.